Maria Caterina Micò

Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial

Alessandro Rambaldi, Anna Grassi, Arianna Masciulli et al. · The Lancet Oncology · 2015 · 176 citations · Full text

Hematological Malignancy, Transplantation, Marrow Transplantation +11

Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab

Alessandro Rambaldi, Giuseppe Gritti, Maria Caterina Micò et al. · Immunobiology · 2020 · 148 citations · Full text

Inflammation, Thrombosis, Vascular Disease +10

Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial

Dietrich W. Beelen, Rudolf Trenschel, Matthias Stelljes et al. · The Lancet Haematology · 2019 · 147 citations · Full text

Safety and efficacy of narsoplimab in pediatric and adult patients with transplant-associated thrombotic microangiopathy: a real-world experience

Marta Castelli, Maria Caterina Micò, Anna Grassi et al. · Bone Marrow Transplantation · 2024 · 18 citations · Full text

Safe and Effective Treatment of Graft Versus Host Disease with Platelet Lysate-Expanded Mesenchymal Stromal Cells: A Prospective, Multicentric, Phase 1 Study

Giovanna Lucchini, Martino Introna, Erica Dander et al. · Biology of Blood and Marrow Transplantation · 2013 · 13 citations · Full text

Cell Therapy, Immunology, Pathology +23